A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis

Exclusion Criteria

• •Blood dyscrasias including confirmed: 1. Hemoglobin \<9 g/dL or Hematocrit \<30%; 2. White blood cell count \<3,000 cu.mm. Absolute neutrophil count \<1,200 cu.mm; 4. Platelet count \<100,000/L
• •History of any other autoimmune rheumatic disease other than Sjogren's syndrome
• •No malignancy or history of malignancy.
• •History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug
• •Patients who have failed any TNFi for either lack of efficacy or a TNFi mechanism related adverse event.
• •Patients who have previously received adalimumab therapy for any reason.
• •Patients who are contraindicated for treatment with adalimumab in accordance with the approved local label.
• •Patients meeting the New York Heart Association Class III and Class IV Congestive Heart failure